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Changes in the amount and localization of human ribosomal proteins during apoptosis
were determined. When total lysates of Jurkat cells undergoing apoptosis induced by
doxorubicin were analyzed by Western blotting, degradation of three ribosomal pro-
teins, S18, L5, and L14, was detected at 48 h after the induction of apoptosis. Decreases
in the amounts of these three ribosomal proteins were also observed in ribosome-en-
riched fractions. These changes were partly abolished by the addition of the pan-cas-
pase inhibitor z-VAD-fmk. Moreover, formation of the 80S ribosome complex appeared to
be inhibited at 48 h after apoptosis induction. On the other hand, the rate of protein syn-
thesis, assessed by measuring the incorporation of [38S]Met into bulk proteins,
decreased as early as 12 h after the addition of doxorubicin. These results indicate that
changes in the amount of ribosomal proteins and the overall structure of ribosomes in
apoptosing cells occur after protein synthesis declines. Finally, analyses by flow cytome-
try, immunofluorescence, and Western blotting showed that six ribosomal proteins, S15,
PO, L5, L6, L36a, and L41, were relocalized and expressed at the cell surface during apo-
ptosis. The above results collectively indicate that ribosomes are structurally altered in
apoptotic cells following inactivation of protein synthesis.
Key words: apoptosis, protein degradation, protein synthesis, ribosomal protein,
ribosome.
Degradation of chromosomal DNA at the last stage in the though the precise function of individual ribosomal proteins
process of apoptosis should result in the complete cessation and RNA has not yet been clarified, it is reasonable to
of gene expression in cells fated to die. However, the rate of expect that the inhibition of protein synthesis in apoptotic
protein synthesis decreases even before chromosomal DNA cells is the consequence of structural modification of these
is degraded (1^1), suggesting the presence of an active molecules. In fact, the 28S ribosomal RNA is selectively
mechanism that inhibits gene expression at the level of degraded in apoptotic cells (3, 5-7). This event occurs at rel-
protein synthesis in apoptotic cells. The molecular basis for atively early stages of apoptosis via both caspase-depen-
this event, however, is not fully understood. dent and -independent mechanisms. It is, however, not
A variety of proteins and nucleic acids are involved in clear whether degradation of the 28S RNA leads to struc-
protein synthesis. The ribosome stands at the center of the tural changes of ribosomes or the inhibition of protein syn-
translational machinery, and the eukaryotic 80S ribosome thesis. On the other hand, factors that are closely related to
complex consists of two subunits, 40S and 60S, each of the translation reaction have been shown to undergo degra-
which contains a large number of proteins and RNA. Al- dation in apoptotic cells: eukaryotic translation initiation
factors eIF2, eIF3, eIF4B, and eIF4G are degraded in a
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sis is S19; it appears to be covalently dimerized and
secreted from apoptotic cells (11-14). Moreover, the modi-
fied S19 serves as a chemoattractant specific for macroph-
ages (12). Two more reports suggest the structural modi-
fication of ribosomes during apoptosis: cleavage or at least
modification of the 60S ribosome subunit protein PO (15)
and destruction of polysomes (1). These findings indicate
that ribosomal proteins and the ribosome complex are
structurally modified in apoptotic cells, and suggest that
some ribosomal proteins have extra-ribosomal functions.
However, the previous studies dealt with only a limited
number of ribosomal proteins, and changes in the overall
structure of the ribosome in apoptotic cells have not been
intensively investigated- Nadano et al. recently examined
structural changes of ribosome subunits and proteins using
anti-ribosomal protein antibodies and found that the
amount of S l l decreases in human tumor-derived cells
undergoing staurosporine-induced apoptosis (16). This
change seemed to occur in a cell type-specific manner it
was evident in four different cell lines derived from human
breast carcinoma, but not in cells from other types of
tumors (26). Here we analyzed the amount, structure and
localization of ribosomal proteins in apoptotic human leu-
kemia cells using polyclonal antibodies raised against pep-
tides corresponding to partial amino acid sequences of 79
human ribosomal proteins.
MATERIALS AND METHODS
Cell Culture and Induction of Apoptosis—Human T-cell
leukemia Jurkat cells were maintained in RPMI 1640
medium (Nissui Pharmaceutical, Tokyo) with 10% fetal
bovine serum at 37°C in a humidified atmosphere of 5%
CO2 in air. The cells (2 x 106 cells/ml) were induced to
undergo apoptosis by treatment with the DNA-intercalat-
ing anticancer drug doxorubicin (17) (0.3 jig/ml) (Sigma, St.
Louis, MO, USA) or the agonistic anti-human Fas mono-
clonal antibody CH11 (18) (0.1 ng/ml) (MBL, Nagoya).
When ribosome-enriched fractions were prepared (see
below), Jurkat cells at a density of 1 x 106 cells/ml were
treated with 1.5 (J-g/ml doxorubicin. The progress of apopto-
sis was almost the same under these conditions. The induc-
tion of cell death was assessed by measuring the exclusion
of trypan blue from cells (integrity of the plasma mem-
brane), the stainability of the nucleus with Hoechst 33342
(condensation of chromatin), and the binding of fluorescein
isothiocyanate (FITC)-labeled annexin V to the cell surface
[externaUzation of the membrane phospholipid phosphati-
dylserine (PS)] as described previously (19). To inhibit cas-
pase-dependent apoptosis, Jurkat cells were pre-incubated
for 1 h with the pan-caspase inhibitor z-VAD-fmk (20 uM)
(Peptide Institute, Osaka), then treated with doxorubicin in
the presence of the inhibitor.
Preparation of Protein Samples for Analysis of Ribosomal
Proteins and Subunits—Whole-cell lysates were obtained
by lysing cells directly with the buffer for sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis [62.5 mM
Tris-HCl (pH 6.8), 2.5% SDS, 2.5% 2-mercaptoethanol]. The
fractions enriched in ribosomes were prepared from the
liver of adult male Donryu rats or Jurkat cells according to
the method of Bommer et al. (20). Briefly, tissues or cells
were homogenized in a buffer containing 0.25 M sucrose
and centrifuged at 12,000 xg. The post-mitochondrial super-
natants were layered on a buifer containing 1 M sucrose
and centrifuged at 260,000 xg. The pellete were suspended
in a buifer containing 0.25 M sucrose and sedimented
again through 1 M sucrose. The final pellets were collected
and used as the ribosome fraction. To obtain cell surface
proteins, Jurkat cells that had been treated with doxorubi-
cin (0.3 jig/ml) for 24 h and still possessed intact plasma
membranes were labeled with biotin (NHS-LC-Biotin;
Pierce, Rockford, EL, USA), lysed in a buffer consisting of 10
mM Tris-HCl (pH 7.8), 1% Nonidet P-40, 0.25 M NaCl, and
1 mM EDTA, and centrifuged. The supernatants were mix-
ed with streptavidin-conjugated magnetic beads (Dyna-
beads M-280 Streptavidin; Dynal, Oslo, Norway), and
bound proteins were collected and used as the cell surface
proteins.
Western Blotting—Anti-human ribosomal protein anti-
bodies were obtained by immunizing rabbits with keyhole
limpet hemocyanin-conjugated synthetic peptides that con-
tained amino acid sequences (10—13 residues) correspond-
ing to 33 small subunit and 46 large subunit proteins of the
human ribosome, as described previously (21). Protein sam-
ples were electrophoresed on a 15% SDS-polyacrylamide
gel, and the separated proteins were transferred onto a
polyvinylidene difluoride membrane (Immobilon P; Milli-
pore, Bedford, MA, USA). The membrane was first reacted
with an anti-ribosomal protein antiserum, then with alka-
line phosphatase-conjugated anti-rabbit IgG (Bio-Rad,
Hercules, CA, USA), and signals were chemiluminescentiy
visualized using Immun-Star substrates (Bio-Rad). In some
experiments, the specificity of the antibody binding was
examined by pre-incubating the first antibodies for 1 h with
excess amounts of the corresponding antigen peptides prior
to the reaction with the membrane. To analyze the forma-
tion of the ribosome complex, we employed a newly devel-
oped method (16). Ribosome-enriched fractions were elec-
trophoretically separated on a composite gel consisting of
polyacrylamide (2%) and agarose (0.7%), and ribosome sub-
units were detected by Western blotting as described above.
Analysis of Protein Synthesis—Jurkat cell cultures were
exposed to doxorubicin (0.3 ^g/ml) for various periods, then
pulse-labeled for 20 min in Met-free RPMI 1640 medium
(Sigma) containing L-P^Met (110 jiCi/ml) (EasyTag; NEN
Life Science Products, Boston, MA, USA). The harvested
cells were lysed by the addition of 50 mM Tris-HCl (pH
7.5), 0.15 M NaCl, 5 mM EDTA, 1 mM phenylmethylsulfo-
nyl fluoride, and 1% Triton X-100 and centrifuged, the
supernatants were separated by electrophoresis in a 10%
SDS-polyacrylamide gel, and the proteins were visualized
by autoradiography. Cell-free protein synthesis was carried
out using a reticulocyte lysate system (Promega, Madison,
WI, USA). The lysates were incubated with oligo d(T)-
selected Jurkat cell RNA (0.2 mg/ml) and a mixture of
amino acids including L-p*S]Met in the presence or absence
of doxorubicin (0.3 |JLg/ml) at 30°C for 90 min, and the prod-
ucts were detected as described above.
Flow Cytometry—Jurkat cells were harvested, washed
with phosphate-buffered saline, and successively reacted
with anti-ribosomal protein antisera and FITC-labeled
anti-rabbit IgG (Lmmunotech, Marseilles, France). The
cells were then analyzed in a flow cytometer (Epics-XL;
Coulter, Hialeah, FL, USA). To examine the specificity of
the binding of the first antibodies, the reaction was done in
the presence of the corresponding antigen peptides.
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Immunofluorescence—Cells were smeared on 3-amino-
propyltriethoxysilane-coated slide glasses and successively
treated with anti-ribosomal protein IgG that had been pre-
pared by protein A-Sepharose chromatography, a biotiny-
lated anti-rabbit IgG antibody (Vector, Burlingame, CA,
USA), and Alexa Fluor 488-conjugated streptavidin (Molec-
ular Probes, Eugene, OR, USA). The samples were washed
and examined under a confocal laser scanning microscope
(LSM 510; Carl Zeiss, Jena, Germany). To simultaneously
detect a ribosomal protein and a cell surface protein, cells
were treated with the anti-L5 antibody and the anti-Fas
antibody CH11, and smeared on slide glasses. They were
further reacted with a biotinylated anti-rabbit IgG anti-
body/Alexa Fluor 488-conjugated streptavidin and Cy3-
conjugated anti-mouse IgM (Jackson ImmunoResearch,
West Grove, PA, USA), and analyzed by confocal micros-
copy.
RESULTS
Detection of Ribosomal Proteins by Western Blotting—
Antisera were obtained from rabbits that had been immu-
nized with synthetic peptides corresponding to partial
amino acid sequences of 33 small and 46 large human ribo-
somal subunit proteins, and tested for their ability to bind
to native ribosomal proteins. For this purpose, whole-cell
lysates of Jurkat cells and ribosome-enriched fractions of
rat liver were analyzed by Western blotting. As shown in
Fig. 1, both samples gave signals, though with varying
intensities, at the positions corresponding to the expected
molecular masses of 11 small subunit proteins, Sa, S3a,
S4X, S8, Sl l , S12, S14, S15, S18, S24, and S30, and 17
large subunit proteins, L5, L7, L7a, L8, L9, L13, L13a, L14,
L15, L17, L18, L28, L31, L34, L35a, L36a; and L39. The
antisera that failed to react with the corresponding riboso-
mal proteins probably recognized only the structure specific
to the antigen peptides. We then used the antisera recog-
nizing the above 28 ribosomal proteins to determine whe-
ther the amounts of these proteins changed during the pro-
cess of apoptosis.
Decrease in Amount of Ribosomal Proteins during Apop-
tosis—Jurkat cells were induced to undergo apoptosis by
treatment with doxorubicin. Such treatment caused typical
apoptotic changes in Jurkat cells, such as loss of plasma
membrane integrity, chromatin condensation, and external-
izatdon of PS to the cell surface (Fig. 2). Whole-cell lysates
were prepared from Jurkat cells that had been exposed to
the drug for various lengths of time, and subjected to West-
ern blotting with the 28 kinds of anti-ribosomal protein
antisera (Fig. 3A). The antisera were reacted with the blot-
ted membranes in the presence or the absence of the corre-
sponding antigen peptides to test the specificity of the
signals. Most ribosomal proteins did not show changes in
response to doxorubicin, as exemplified by the result with
the anti-S4X antiserum. However, the levels of S18, L5,
and L14 were affected by doxorubicin: the amounts of S18
decreased, and signals with faster mobility appeared on the
gels stained with anti-L5 and -L14 antibodies as the time of
drug treatment was increased. These changes all became
apparent at 48 h or later after the induction of apoptosis. It
is thus likely that these three ribosomal proteins undergo
degradation during apoptosis. We next examined whether
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Fig. 1. Detection of ribosomal proteins by Western blotting. Ribosome-enriched fractions of rat liver (L) (10 or 75 mj protein) and whole-
cell lysates of Jurkat cells (J) (40 or 80 n# protein) were analyzed with 79 kinds of anti-human ribosomal protein antisera.The results for an-
tisera that gave specific signals are presented. The arrows indicate the positions of ribosomal proteins. The positions of molecular mass mark-
ers are shown at the left (in kilodalton).
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Fig. 2. Induction of apoptosis in Jurkat cells by doxorubicin,
Jurkat cells were incubated with doxorubicin for the indicated peri-
ods and examined for biochemical changes indicating apoptosis. A:
The integrity of the plasma membrane was examined by staining
cells with the trypan blue dye The relative number of trypan blue-
negative cells is shown as a percentage. Closed and open circles indi-
cate cells treated and not treated with doxorubicin, respectively. B:
The occurrence of chromatin condensation was examined by staining
cells with Hoechst 33342. The relative number of cells containing
condensed chromatin is shown as a percentage Closed and open cir-
cles indicate cells treated and not treated with doxorubicin, respec-
tively. C: The presence of PS on the cell surface was examined in a
flow cytometer by staining cells with FITC-labeled annexin V and
propidium iodide The numbers indicate the relative cell number (as
a percentage) present in the corresponding areas. The propidium io-
dide-negative cells (bottom area in the left panels) were gated and
re-plotted in the right panels, and the cells corresponding to the
right peak possess externalized PS.
the same changes occurred in the ribosome complex. To do
this, fractions enriched in ribosomes were prepared from
apoptotic Jurkat cells by density gradient centrifugation
and analyzed by Western blotting (Fig. 3B). The decreases
in the amounts of the three proteins were observed with
the ribosome fraction more significantly than with whole-
cell lysates. However, the presumed degradation products
of L5 and L14 were not detectable. These results indicate
that three ribosomal proteins, S18, L5, and L14, are de-
graded upon induction of apoptosis, and suggest that the
degraded proteins are dissociated from the ribosome com-
plex, resulting in the appearance of ribosomes deficient in
these proteins in apoptotic cells.
To examine whether these changes are restricted to cells
undergoing doxorubicin-induced apoptosis, Jurkat cells
were treated with the agonistic anti—human Fas antibody
CH11, and their lysates were analyzed by Western blotting.
As clearly seen in Fig. 4, almost the same changes were
observed with cells undergoing Fas-mediated apoptosis.
This indicates that degradation of the three ribosomal pro-
teins occurs in apoptotic Jurkat cells independently of the
mode of apoptosis induction.
We then examined whether such changes occurred dur-
ing caspase-dependent apoptosis. Jurkat cells were treated
with doxorubicin in the presence of the pan-caspase inhibi-
tor z-VAD-fmk, and whole-cell lysates were analyzed for
ribosomal proteins by Western blotting. Treatment with the
caspase inhibitor reduced the fraction of cells with chroma-
tin condensation to less than 20% (Fig. 5A). Under these
conditions, the changes in the three ribosomal proteins
were largely, though not completely, abolished (Fig. 5B).
This indicates that the degradation of ribosomal proteins is
partly dependent on the action of caspases.
Decrease in Amount of 80S Ribosome Complex in Apop-
totic Cells—The loss of even a few kinds of ribosomal pro-
teins might influence the structural integrity of the ribo-
some complex. To examine this possibility in apoptotic cells,
we examined the presence of ribosome complexes in doxo-
rubicin-treated cells. Ribosome-enriched fractions prepared
from normal Jurkat cells were separated in an agarose/
polyacrylamide composite gel and analyzed by Western
blotting with anti-ribosomal protein antisera (Fig. 6A).
Two distinct signals, which almost completely disappeared
when the antibody reaction was carried out in the presence
of the corresponding antigen peptides, were obtained with
either the antd-S4X or antd-L34 antdserum. The signal with
slower mobility was detected at almost the same positions
with the two antisera and thus considered to be the 80S
complex, which derived from either polysomes or the 80S
ribosome pool. We concluded that the three signals were, in
the order of their migration in the gel, derived from 40S,
60S, and 80S ribosome complexes.
We then tested the ribosome-enriched fractions prepared
from Jurkat cells that had been exposed to doxorubicin for
various lengths of time (Fig. 6B). When the samples were
analyzed with the anti-S4X antiserum, the signal from the
80S complex decreased as the culture period was increased,
whereas that from the 40S subunit was unchanged. Simi-
larly, the analysis with the anti-L34 antiserum showed a
decrease in the intensity of the 80S complex with a mar-
ginal change of the 60S signal. These changes became ap-
parent at 48 h after induction of apoptosis, when ribosomal
proteins S18, L5, and L14 started to be degraded. These
results suggest that formation of the 80S complex was in-
hibited in the later stages of apoptosis.
Decline of Protein Synthesis at Early Stage of Apoptosis—
To study the correlation between the above findings and
changes in the rate of protein synthesis, Jurkat cells that
had been treated with doxorubicin for various lengths of
time were pulse-labeled with a radiolabeled amino acid,
and the amount of labeled proteins was determined by
SDS-polyacrylamide gel electrophoresis and autoradiogra-
phy. As shown in Fig. 7 A, signals derived from labeled pro-
teins became weakened as early as 12 h, and undetectable
at 24 h, after the induction of apoptosis. This appeared not
J. Biochem.
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Fig. 3. Changes in the amounts of
ribosomal proteins in doxorubicin-
treated Jurkat cells. AJ Whole-cell ly-
sates of Jurkat cells that had been
treated with doxorubicin for the indi-
cated periods were analyzed by West-
ern blotting with 28 kinds of anti-
ribosomal protein antisera. Results
showing changes in the signals of ribo-
somal proteins (S18, L5, and L14) to-
gether with an example of the results
with no change (S4X) are presented.
Reactions of the antisera with the blot-
ted membranes were done in the pres-
ence (+) or absence (—) of the corre-
sponding antigen peptides. The arrows
and arrowheads indicate the intact ri-
bosomal proteins and presumed degra-
dation products, respectively. The posi-
tions of molecular mass markers are
shown at the right of each panel. B: Ri-
bosome-enriched fractions prepared
from Jurkat cells that had been treated
with doxorubicin were analyzed by
Western blotting with the three anti-
sera. The symbols are the same as
those used in A.
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Fig. 4. Changes in the amounts of ribo-
somal proteins in CH11-treated Jurkat
cells. Whole-cell lysates of Jurkat cells that
had been treated with the anti-Fas antibody
CH11 for the indicated periods were ana-
lyzed by Western blotting with three anti-ri-
bosomal protein antisera. The symbols are
the same as those used in Fig. 3A.
to be the direct effect of doxorubicin on translation, since
protein synthesis in a cell-free system was not altered in
the presence of the drug (Fig. 7B). These results indicate
that the inhibition of protein synthesis during apoptosis
precedes the structural changes of ribosomes, that is, the
degradation of ribosomal proteins and the disappearance of
the 80S ribosome complex.
Cell Surface Expression of Ribosomal Proteins—Some
ribosomal proteins have been shown to be released from
ribosomes during apoptosis. In particular, the small sub-
unit protein SI is transferred to the membrane bleb of apo-
ptotic cells (10). We therefore examined whether any ribo-
somal proteins are expressed on the surface of apoptotic
cells. Jurkat cells were treated with doxorubicin for 24 h, at
which time they showed chromatin condensation and PS
externalization but were not stained with propidium iodide
(see Fig. 2), and were thus considered to have intact plasma
membranes. These cells as well as normal Jurkat cells were
Vol. 131, No. 3,2002
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Fig. 5. Caspase-dependency of change of ribosomal proteins in
doxorubicin-treated Jurkat cells. A; Jurkat cells were treated
with doxorubicin for 48 h in the presence or absence of the pan-
caspase inhibitor z-VAD-fmk. The fraction of cells containing con-
densed chromatin is shown. B: Whole-cell lysates of Jurkat cells that
had been treated with doxorubicin for 48 h (L5 and L14) or 72 h (S18)
in the presence or absence of the inhibitor were analyzed for changes
of ribosomal proteins by Western blotting. The symbols are the same
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Fig. 6. Failure of formation of the 80S ribosome complex in
apoptotic Jurkat cells. A; Ribosome-enriched fractions from nor-
mal Jurkat cells were separated on a composite gel consisting of aga-
rose and polyacrylamide, and subjected to Western blotting with
anti-ribosomal protein antisera. Incubations of the antisera with the
blotted membranes were performed in the presence or absence of the
corresponding antigen peptides. The positions of ribosome complexes
and the top of gels are indicated at the left. B: Jurkat cells that had
been treated with doxorubicin for the indicated periods were ana-




Fig. 7. Decline of protein synthesis in doxorubicin-treated
cells. A; Jurkat cells treated with doxorubicin or left untreated for
the indicated periods were analyzed for the rate of protein synthesis
as described in the "MATERIALS AND METHODS" section. B: Cell-
free protein synthesis with reticulocyte lysates was carried out in
the presence or absence of doxorubicin and exogenously added RNA,
and analyzed as in A. The arrowheads indicate RNA-dependent sig-
nals.
subjected to flow cytometry, immunofluorescence, and
Western blotting with specific antibodies to determine the
surface expression of ribosomal proteins.
We first determined which antisera were usable in flow
cytometry. For this purpose, normal Jurkat cells were per-
meabilized by treatment with methanol and analyzed by
flow cytometry with 79 kinds of antisera in the presence or
absence of the corresponding antigen peptides. Twenty-
eight antisera recognizing 10 small subunit proteins, Sa,
S2, S4X, Sl l , S14, S15, S18, S24, S29, and S30, and 18
large subunit proteins, P0, P2, L3, L4, L5, L6, L7, L10,
L14, L23a, L29, L35a, L36, L36a, L37, L38, L39, and L41,
J. Biochem.
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Fig. 8. Presence of ribosomal proteins at the surface of apop-
totic Jurkat cells. A; Jurkat cells treated with doxorubicin (solid
lines) or left untreated (broken lines) were analyzed by flow cytome-
try with 28 kinds of antd-ribosomal protein antdsera. Results for anti-
sera that showed more efficient binding to doxorubicin-treated cells
are presented. B: The same cells were subjected to immunofluores-
cence with the six anti-ribosomal protein IgGs or control normal rab-
bit IgG. Phase-contrast (left) and fluorescence (right) views of the
same fields are shown. Bar = 10 |im. C: Doxorubicin-treated Jurkat
cells were simultaneously examined for the presence of L5 and Fas by
immunofluorescence. Note that staining of the cell interior in the
right two panels is due to fluorescence from DNA-bound doxorubicin.











Fig. 9. Detection of ribosomal
proteins in surface proteins
of apoptotic Jurkat cells.
Surface proteins of doxorubicin-
treated (A) or normal (N) Jurkat
cells were analyzed by Western
blotting with anti—ribosomal
protein antisera or an antibody
recognizing the transcription
factor C/EBPp. Lanes "C" con-
tained whole-cell lysates of dox-
orubicin-treated Jurkat cells as
a positive control. The arrows
point to the positions of specific
signals.
bound to the permeabilized Jurkat cells more intensely
than a control rabbit serum in a manner inhibitable by the
cognate antigen peptides (data not shown). We thus used
these antisera to analyze doxorubicin-treated cells for the
surface expression of ribosomal proteins. As depicted in Fig.
8A, six antibodies bound to apoptotic cells more efficiently
than to normal cells. To examine the binding of these anti-
bodies to the surface of apoptotic Jurkat cells by another
method, the same cells were subjected to immunofluores-
cence and analyzed by confocal microscopy. Most antibod-
ies, except for two with only a marginal effect, gave signals
at the periphery of doxorubicin-treated cells at levels well
beyond background (Fig. 8B). Furthermore, the signals
with the anti-L5 antibody were entirely included within
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those obtained with an antibody recognizing the cell sur-
face protein Fas (Fig. 8C). Finally, we confirmed the surface
expression of ribosomal proteins by Western blotting. Sur-
face proteins were isolated from either doxorubicin-treated
or untreated Jurkat cells and examined for the presence of
S15, L5, and L36a (Fig. 9). All the three ribosomal proteins
were detectable only with the surface proteins prepared
from apoptotic cells. In contrast, the same protein sample
did not give a signal with a control antibody recognizing a
protein localized in the nucleus. All the above results collec-
tively indicate that five large subunit proteins, PO, L5, L6,
L36a, and L41, and one small subunit protein, S15, are
present on the surface of apoptotic Jurkat cells.
DISCUSSION
We analyzed changes in the amount and localization of
eukaryotic ribosomal proteins during apoptosis using spe-
cific antibodies. Western blotting analyses of 28 ribosomal
proteins revealed that three of them, S18, L5, and L14,
underwent degradation during apoptosis induced by the
anticancer drug doxorubicin or the agonistic anti-Fas mono-
clonal antibody, and suggested that ribosomes with de-
creased amounts of particular ribosomal proteins exist in
apoptotic cells. It is not likely that these proteins are
cleaved directly by caspases since they contain no amino
acid sequences that are targeted by caspases. These results
are distinct from those previously obtained in the analysis
with human breast carcinoma cells, in which the amount of
S l l specifically decreased during apoptosis (16). Changes
in the amount of ribosomal proteins in apoptotic cells are
thus likely to be cell-type specific. Moreover, the amount of
the 80S ribosome complex decreased in apoptotic cells, sug-
gesting that the formation of the complex was inhibited.
Although such deficient ribosomes are most likely not func-
tional in protein synthesis, the above changes in the struc-
ture of ribosomes do not seem to be the major cause of the
decrease in the rate of protein synthesis during apoptosis,
because protein synthesis declined well before the changes
in the ribosomal proteins became detectable. In contrast,
degradation of the 28S ribosomal RNA paralleled the rate
of protein synthesis during apoptosis (3). It thus seems that
the change in the structure of ribosomal RNA is more im-
portant for the inhibition of protein synthesis than changes
in ribosomal proteins at early stages of apoptosis. We spec-
ulate that the degradation of ribosomal proteins completely
inactivates cellular functions at the final step in the process
of apoptosis.
Another possible role of the structural changes of ribo-
somes is regulation of the extra-ribosomal functions of ribo-
somal proteins. Yamamoto and colleagues have shown that
S19, which is dimerized and released from apoptotic cells,
functions as a chemoattractant (14). They proposed that
macrophages are attracted by the modified S19 to sites rich
in apoptotic cells. We were unable to verify whether dimer-
ized S19 is released from apoptotic Jurkat cells, since our
antiserum raised against the S19 sequence did not react
with the native protein. As another possible target func-
tion, Casciola-Rosen et al. have shown that cellular compo-
nents including a ribosomal protein translocate to the
membrane bleb in apoptotic cells and suggested the possi-
bility that such molecules serve as autoantdgens (10). Our
flow cytometric analyses with 28 kinds of anti-ribosomal
protein antibodies suggested that several ribosomal pro-
teins move to the surface of apoptotic cells during apopto-
sis, and this was confirmed by hnmunofluorescence and
Western blotting analyses. Although the results reported by
Casciola-Rosen et al. do not necessarily mean the surface
expression of the ribosomal protein, our results clearly
showed that several proteins exist at the surface of apop-
totic Jurkat cells. Any proteins that are normally restricted
to the cell interior should readily be detected by the im-
mune surveillance system when they are exposed to the
cell surface. A probable consequence of the immune recog-
nition is the phagocytdc clearance of cells possessing such
externalized molecules. Externalized ribosomal proteins
could thus serve as markers for recognition of apoptotic
cells by phagocytic cells. Apoptotic cells are rapidly and
selectively eliminated from the organism by phagocytosis,
and this is defined by specific recognition of target cells by
phagocytes (22). A variety of molecules, including proteins,
phospholipids and sugars, have been proposed to act as
phagocytosis markers when expressed on the surface of
apoptotic cells (22). Phagocytic cells such as macrophages
recognize those markers using specific receptors and subse-
quently engulf apoptotic cells (22). There is as yet no evi-
dence that ribosomal proteins act as phagocytosis markers.
Experiments are now in progress to examine whether any
ribosomal proteins that were detectable on the surface of
apoptotic Jurkat cells are involved in the recognition of
apoptotic Jurkat cells by macrophages.
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